Author

Jun Hwa Hong

Institutions: Eulji University, Daejeon Eulji Medical Center, Eulji University

Observed institutions: Chungnam National University, Eulji University, Daejeon Eulji Medical Center, Eulji University, Chungnam National University Hospital

ORCID: 0000-0002-8693-1038

Observed ORCID: 0000-0002-8693-1038

OpenAlex ID: A5109603313

Urinary Chiro- and Myo-Inositol Levels as a Biological Marker for Type 2 Diabetes Mellitus

2012 · Jun Hwa Hong, Hye Won Jang, et al. · Disease Markers · 33

Efficacy and safety of a fixed‐dose combination of dapagliflozin and linagliptin ( AJU ‐ A51 ) in patients with type 2 diabetes mellitus: A multicentre, randomized, double‐blind, parallel‐group, placebo‐controlled phase III study

2024 · Jun Hwa Hong, Myung Jin Kim, et al. · Diabetes Obesity and Metabolism · 8

Efficacy and Safety of HD-6277, a Novel G Protein-Coupled Receptor 40 Agonist, in Individuals with Type 2 Diabetes Mellitus: A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 2 Clinical Trial

2025 · Yong-ho Lee, Kyung Wan Min, et al. · Diabetes & Metabolism Journal · 2

Effectiveness and Safety of Evogliptin in Patients With Type 2 Diabetes Mellitus: A Multicenter, Prospective, Observational Study

2026 · Jun Hwa Hong, Sung Hoon Yu, et al. · Diabetes Obesity and Metabolism · 1

Efficacy and safety of adding a fourth oral antidiabetic drug versus metformin dose escalation in patients with type 2 diabetes inadequately controlled on triple oral combination therapy ( EFFORT ): A 24‐week, randomized, open‐label, multicenter trial

2026 · So Ra Kim, Jun Hwa Hong, et al. · Diabetes Obesity and Metabolism

Author response for "Efficacy and safety of a fixed‐dose combination of dapagliflozin and linagliptin ( AJU ‐ A51 ) in patients with type 2 diabetes mellitus: A multicentre, randomized, double‐blind, parallel‐group, placebo‐controlled phase III study"

2024 · Jun Hwa Hong, Myung Jin Kim, et al. · Publons reviews and discussion

Author response for "Efficacy and safety of a fixed‐dose combination of dapagliflozin and linagliptin ( AJU ‐ A51 ) in patients with type 2 diabetes mellitus: A multicentre, randomized, double‐blind, parallel‐group, placebo‐controlled phase III study"

2024 · Jun Hwa Hong, Myung Jin Kim, et al. · Publons reviews and discussion

Author response for "Comparison of the effects of gemigliptin versus glimepiride on cardiac function in patients with type 2 diabetes uncontrolled with metformin: the Gemi‐Heart study"

2023 · Seung Min Chung, Jun Sung Moon, et al. · Publons reviews and discussion

Works count: 8

Citation count: 44

H-index: 2

I10-index: 1